At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 4 enrolled
Drug / intervention
Rapamycin 8% Ointment +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Topical Rapamycin Ointment on Keloid Regression: A Pilot Study in Human Subjects (RAPA-Keloid)
The University of Texas Health Science Center at San Antonio·interventional·Posted Aug 8, 2019·Updated Sep 29, 2021
In Brief
A Early Phase 1 clinical trial evaluating Rapamycin 8% Ointment and Placebo for Keloid. Completed, enrolled 4 participants across 1 site.
Detailed Summary
1. To test whether topical rapamycin regresses established keloids in humans by measuring surface area and height changes in the scar over time (6 months) 2. To test safety of product and feasibility of conduct for future clinical trial
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKeloid
CountriesUnited States
Collaborators--
Timeline
Early Ph 1CompletedFinished
2020202120222023202420252026
First PostedAug 2019
Enrollment StartJan 2020
Primary CompletionAug 2020
Study CompletionMay 2021
TodayJul 2026
First PostedAug 8, 2019
Enrollment StartJan 24, 2020
Primary CompletionAug 24, 2020
Study CompletionMay 2, 2021
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 6.9 years ago
Interventions
Rapamycin 8% Ointmentdrug
A compounded ointment containing 8% rapamycin
Placebodrug
Petrolatum ointment placebo